期刊
NATURE REVIEWS IMMUNOLOGY
卷 18, 期 1, 页码 5-18出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nri.2017.97
关键词
-
类别
资金
- U.S. National Institutes of Health [AI068730, AI030040]
- National Science Foundation [1423304]
- European Community's Seventh Framework Programme [602699]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI030040, P01AI068730, R01AI030040] Funding Source: NIH RePORTER
In tumour immunology, complement has traditionally been considered as an adjunctive component that enhances the cytolytic effects of antibody-based immunotherapies, such as rituximab. Remarkably, research in the past decade has uncovered novel molecular mechanisms linking imbalanced complement activation in the tumour microenvironment with inflammation and suppression of antitumour immune responses. These findings have prompted new interest in manipulating the complement system for cancer therapy. This Review summarizes our current understanding of complement-mediated effector functions in the tumour microenvironment, focusing on how complement activation can act as a negative or positive regulator of tumorigenesis. It also offers insight into clinical aspects, including the feasibility of using complement biomarkers for cancer diagnosis and the use of complement inhibitors during cancer treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据